Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

North Charleston, South Carolina Clinical Trials

A listing of North Charleston, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (27) clinical trials

ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Solid Tumors With PIK3CA / AKT / PTEN Mutations

AKT inhibitor may decrease or arrest growth of cancer cells that depends on the presence of a protein called AKT. A number of genes, namely, PIK3CA, AKT and PTEN, may cause the AKT to behave abnormally, so by blocking the action of these genes on AKT with the drug like ...

Phase

4.38 miles

Learn More »

Atezolizumab Pemetrexed Disodium Cisplatin and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

PRIMARY OBJECTIVES: I. To evaluate if the regimen of neoadjuvant cisplatin-pemetrexed disodium (pemetrexed)-atezolizumab, surgery +/- radiation, then maintenance atezolizumab is feasible and safe for patients with resectable malignant pleural mesothelioma. SECONDARY OBJECTIVES: I. To evaluate progression free survival (both by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 and also ...

Phase

5.28 miles

Learn More »

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

This study will examine the safety and anticancer activity of enfortumab vedotin given intravenously as monotherapy and in combination with other anticancer therapies to patients with urothelial cancer. The primary goal of the study is to determine the safety, tolerability, and efficacy of enfortumab vedotin alone and in combination with ...

Phase

5.28 miles

Learn More »

The purpose of this Study is to evaluate the safety and tolerability of INCB053914 alone and in combination with standard therapies in subjects that have advanced cancer.

Phase

5.28 miles

Learn More »

AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy

AGEs are a type of metabolite, or substance, found in the food. The AGE content in food is determined by the types of food you eat and also how you prepare your food. The researchers helping conduct this study have found a potential link between AGE levels and cancer. The ...

Phase

5.28 miles

Learn More »

Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Phase

5.28 miles

Learn More »

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab CIS and GEM; and CIS and GEM Alone in Participants With Previously Untreated Unresectable Locally Advanced or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

The study will have a Run-in portion and an Expansion portion. The Run-in portion will be used to evaluate the safety profile of the PEGCISGEM and PEGCISGEMATEZO treatments prior to evaluating the efficacy and safety of PEGCISGEM and PEGCISGEMATEZO treatments compared with CISGEM treatment in the Expansion portion of the ...

Phase

5.28 miles

Learn More »

A "Window Trial" on Boswellia for Breast Cancer Primary Tumors

To determine whether oral administration of Boswellia serrata causes biological changes related to angiogenesis (CD31), apoptosis (DNA fragmentation), and cell proliferation (Ki67) in primary tumors of breast cancer patients.

Phase

5.28 miles

Learn More »

Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder

CV185118 is a single dose Apixaban PK/PD study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects at risk for thrombosis

Phase

5.28 miles

Learn More »

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The ...

Phase

5.28 miles

Learn More »